Pharmacokinetics of Basiliximab for the Prevention of Graft ‐versus‐Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal‐Intensity Cyclophosphamide and Fludarabine
ConclusionWe suggest a one ‐compartment population model with first‐order elimination to capture the pharmacokinetic profile for basiliximab for this patient population.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Jagdeep T. Podichetty,
Bryan J. Brinda,
Robert P. Nelson,
Alissa H. Karr,
Nagendra K. Prasad,
Sara Quinney,
Susanna Foxworthy Scott,
Patrick J. Kiel Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Anemia | Aplastic Anemia | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Drugs & Pharmacology | Hematology | Leukemia | Lymphoma | Myelodysplastic Syndrome | Restasis | Study | Transplants